Newsletter
Maintenance Infliximab for Immune-Mediated Inflammatory Diseases, Omega-3 Fatty Acids for Depression, DOACs and Atrial Fibrillation, and more

JAMA Editor’s Summary

Maintenance Infliximab for Immune-Mediated Inflammatory Diseases, Omega-3 Fatty Acids for Depression, DOACs and Atrial Fibrillation, and more

Editor's Summary by Gregory Curfman, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the issue.
December 21, 2021

Maintenance Infliximab for Immune-Mediated Inflammatory Diseases, Omega-3 Fatty Acids for Depression, DOACs and Atrial Fibrillation, and more

Editor’s Summary by Gregory Curfman, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the December 21, 2021 issue.

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

Proudly supported by:

cover
Adopting Clinical Trial Technology: The Key to Success for Patients, Sites, & Researchers Adoption of new clinical trial technologies is critical to success. These innovations can lift patient burden, improve patient engagement, and increase equity and access to clinical trials.